School of Mechanical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Biomolecules. 2024 Aug 20;14(8):1036. doi: 10.3390/biom14081036.
The development of vaccines has entered a new era with the advent of nanotechnology, particularly through the utilization of nanoparticles. This review focuses on the role of nanoparticles in enhancing the efficacy and stability of mRNA vaccines. Nanoparticles, owing to their unique properties such as high surface area, tunable size, and their ability to be functionalized, have emerged as powerful tools in vaccine development. Specifically, lipid nanoparticles (LNPs) have revolutionized the delivery of mRNA vaccines by protecting the fragile mRNA molecules and facilitating their efficient uptake by cells. This review discusses the various types of nanoparticles employed in mRNA vaccine formulations, including lipid-based, polymer-based, and inorganic nanoparticles, highlighting their advantages and limitations. Moreover, it explores the mechanisms by which nanoparticles improve immune responses, such as enhanced antigen presentation and the prolonged release of mRNA. This review also addresses the challenges and future directions in nanoparticle-based vaccine development, emphasizing the need for further research to optimize formulations for broader applications. By providing an in-depth analysis of the current advancements in and potential of nanoparticles in mRNA vaccines, this review aims to shed light on their critical role in combating infectious diseases and improving public health outcomes.
随着纳米技术的出现,疫苗的发展进入了一个新时代,特别是通过利用纳米粒子。本综述重点介绍了纳米粒子在提高 mRNA 疫苗的功效和稳定性方面的作用。纳米粒子具有高表面积、可调尺寸和功能化的能力等独特性质,已成为疫苗开发的有力工具。具体而言,脂质纳米颗粒(LNPs)通过保护脆弱的 mRNA 分子并促进其被细胞有效摄取,彻底改变了 mRNA 疫苗的传递方式。本综述讨论了用于 mRNA 疫苗配方的各种类型的纳米粒子,包括基于脂质的、基于聚合物的和基于无机的纳米粒子,突出了它们的优点和局限性。此外,还探讨了纳米粒子如何改善免疫反应的机制,例如增强抗原呈递和延长 mRNA 的释放。本综述还讨论了基于纳米粒子的疫苗开发中的挑战和未来方向,强调需要进一步研究来优化制剂以实现更广泛的应用。通过深入分析纳米粒子在 mRNA 疫苗中的当前进展和潜力,本综述旨在阐明它们在抗击传染病和改善公共卫生成果方面的关键作用。
Biochim Biophys Acta Gen Subj. 2024-3
Hum Vaccin Immunother. 2024-12-31
Vaccines (Basel). 2024-6-29
Sci Rep. 2023-10-5
Med Sci (Basel). 2024-5-22
Curr Opin Biotechnol. 2022-2
Vaccines (Basel). 2025-8-20
Mol Ther Nucleic Acids. 2025-7-29
Discov Oncol. 2025-7-5
Mater Today Bio. 2024-5-29
ACS Appl Mater Interfaces. 2024-4-3
Proc Natl Acad Sci U S A. 2024-3-12
ACS Omega. 2024-1-30
Nat Rev Drug Discov. 2024-4
Biomed Pharmacother. 2024-1